Foundation Medicine
37
4
9
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
13.5%
5 terminated/withdrawn out of 37 trials
79.2%
-7.3% vs industry average
16%
6 trials in Phase 3/4
74%
14 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Role: collaborator
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Role: collaborator
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Role: collaborator
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Role: collaborator
Next Generation Personalized Neuroblastoma Therapy
Role: collaborator
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Role: collaborator
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Role: collaborator
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
Role: collaborator
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Role: collaborator
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Role: collaborator
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Role: collaborator
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Role: collaborator
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Role: collaborator
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Role: collaborator
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Role: collaborator
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Role: collaborator
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Role: collaborator
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Role: collaborator
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Role: collaborator
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Role: collaborator